Authors: Sharon Salt, Editor
In this week’s industry news round-up, we cover the latest headlines on two monoclonal antibodies – ofatumumab and eculizumab – for relapsing multiple sclerosis and neuromyelitis optica spectrum disorder (NMOSD). We also cover the approval of istradefylline as an add-on drug to treat ‘OFF’ episodes for Parkinson’s disease.
Click on the titles below to navigate to each industry highlight:
- Ofatumumab demonstrates superiority over Aubagio® for relapsing multiple sclerosis
- Eculizumab approved by the European Commission for neuromyelitis optica spectrum disorder
- Istradefylline approved as new add-on drug to treat ‘OFF’ episodes for Parkinson’s disease
Ofatumumab demonstrates superiority over Aubagio® for relapsing multiple sclerosis
Novartis (Basel, Switzerland) has reported that ofatumumab (OMB157) has met the primary endpoints to reduce the annualized relapse ratio over Aubagio® (teriflunomide) in two head-to-head Phase III clinical trials (ASCLEPIOS I and II) in people with relapsing forms of multiple sclerosis.
Ofatumumab is a fully human anti-CD20 monoclonal antibody that is self-administered by a once-monthly subcutaneous injection.